Physician profile
Dora I Duque
NPI 1194056549
$3,271.79
in general payments reported to CMS, 2019-2025
19 companies · $952 in 2025
The $952 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $90.64 · 2021: $121 · 2023: $508 · 2024: $1,164 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,623.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $551.13 | 2019-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $532.50 | 2023-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $324.48 | 2024-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $284.76 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $278.41 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $248.76 | 2019-2025 | Aristada, Aristada Initio, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $210.70 | 2019-2025 | Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $161.01 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $159.96 | 2019-2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $148.12 | 2019 | |
| Neurocrine Biosciences, INC. | $105.37 | 2019-2025 | Ingrezza |
| Indivior INC. | $95.26 | 2023-2025 | Perseris, Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $51.34 | 2019-2024 | Trintellix |
| Collegium Pharmaceutical, INC. | $29.08 | 2025 | Jornay Pm |
| Lundbeck LLC | $25.99 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $21.00 | 2019-2020 | |
| Corium, LLC | $16.96 | 2024 | Azstarys |
| Axsome Therapeutics, INC. | $13.96 | 2024 | Auvelity |
| Allergan, INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dora Duque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.